SIDE-BY-SIDE EVIDENCE

Compare evidence.
Keep the context.

Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.

Choose profiles

SIDE-BY-SIDE EVIDENCE VIEW

Compare selected profiles

Evidence comparison · not a treatment ranking

Evidence boundaries, not cross-trial treatment outcomes
Molecule	Erythropoietin / EPO	Insulin	ARA-290 (Cibinetide)
Research Topic	Clinical / Endocrine Pharmacology	Clinical / Endocrine Pharmacology	Tissue / Repair Research
Pharmacology	Erythropoiesis-stimulating hormone / medicine family	Glucose-regulating hormone / product-specific medicine family	Investigational erythropoietin-derived tissue-protective peptide
PrimeCore Class	Class AApproved in a bounded context	Class AApproved in a bounded context	Class BInvestigational
Evidence Grade	Grade AStrong regulatory + clinical evidence	Grade AStrong regulatory + clinical evidence	Grade CEarly human evidence
Evidence boundary	EPO is an erythropoietic hormone and an ambiguous catalogue label, not a verified product identity. Authorised epoetin medicines treat selected anaemias, with risks including hypertension and thrombosis. Specific ESA warnings include stroke, cardiovascular events and tumour progression in defined settings. No endurance-enhancement recommendation is made.	Insulin medicines are essential in defined diabetes settings but can cause life-threatening hypoglycaemia. Human insulin, analogues and premixes differ. A catalogue entry without the exact type, formulation and device cannot identify an authorised medicine or support product switching or bodybuilding use.	Also known as cibinetide, an investigational peptide studied in inflammatory and neuropathy contexts; clinical evidence remains indication-specific.
Unknowns	Insufficient data in the current dataset	Insufficient data in the current dataset	long-term safety, immunogenicity and rare adverse effects whether biomarker changes translate into durable patient-important outcomes effective and safe use in larger, diverse populations current development status and whether confirmatory trials will occur quality and identity of products marketed under ARA-290, cibinetide or pHBSP names current marketing-authorisation status in Thailand and national EU jurisdictions
Limitations	English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) เป้าหมายการรักษาโลหิตจางต้องสมดุลกับความเสี่ยง ไม่ใช่ยิ่งเม็ดเลือดแดงสูงยิ่งดี	English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) การเปลี่ยนชนิด สูตร หรืออุปกรณ์ insulin ต้องประเมินกับผู้รักษา ไม่แปลงหรือเทียบผลิตภัณฑ์จากบทความนี้	The clinical program is based mainly on small, short studies involving related research teams and sponsor participation. Several outcomes were exploratory, subgroup-based or surrogate biomarkers. The diabetic macular edema study was open-label and uncontrolled. No verified Phase 3 confirmatory trial or marketing approval establishes clinical benefit.
Sources	FDA · Epogen prescribing information · 2018 (dated label) EMA · NeoRecormon assessment	EMA · insulin lispro Sanofi; biosimilarity and hypoglycaemia EMA · Humalog assessment	https://precision.fda.gov/uniisearch/srs/unii/9w5677jkda https://www.fda.gov/media/94155/download https://www.fda.gov/media/94164/download https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1721 https://clinicaltrials.gov/study/NCT02039687 https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003016-45/results https://pubmed.ncbi.nlm.nih.gov/23168581/ https://pubmed.ncbi.nlm.nih.gov/24136731/ https://pubmed.ncbi.nlm.nih.gov/28475703/ https://pubmed.ncbi.nlm.nih.gov/25387363/ https://pubmed.ncbi.nlm.nih.gov/32674280/ https://pubmed.ncbi.nlm.nih.gov/29026145/ https://pubmed.ncbi.nlm.nih.gov/32345869/ https://products.mhra.gov.uk/ https://www.ema.europa.eu/en/medicines/download-medicine-data https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list
Read more	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)

This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.

Choose another comparison

Continue reading

Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.

10 questions before drawing conclusions

Compare evidence.Keep the context.

Continue reading

Contact PrimeCoreBio

Compare evidence.
Keep the context.